{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:30:58Z","timestamp":1778567458552,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent studies have suggested a change in the epidemiologic pattern of testicular germ-cell tumors (TGCTs) and advances in therapeutic strategies have led to significant changes in their treatment over the last decades. Treatment guidelines for early-stage testicular cancer recommend de-escalation of therapy by the adoption of surveillance strategies. This study aimed to describe trends in TGCTs diagnosed over the last 30\u00a0years at our center and evaluate the impact of evolving treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 277 TGCT patients treated from 1994 to 2023. Clinical characteristics, treatment patterns, and outcomes were assessed across three 10-year periods. Survival and relapse rates were estimated using Kaplan\u2013Meier methods; significance was set at p\u2009&lt;\u20090.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significant increase in incidence was observed (p\u2009&lt;\u20090.05), along more stage I diagnoses (p\u2009&lt;\u20090.05) and older age at diagnosis, including a higher proportion aged\u2009\u2265\u200940\u00a0years (p\u2009&lt;\u20090.001). Seminoma incidence doubled, while non-seminoma remained stable. In stage I disease, the use of active surveillance increased significantly, while adjuvant chemotherapy declined (p\u2009&lt;\u20090.0005). Recurrence rates slightly decreased but were not statistically significant. Cause-specific 10-year survival improved from 95% to 97.2%, with overall survival stable at\u2009~\u200994%. The risk of second primary malignancies was notable, including contralateral testicular cancer (2.9%) and second malignant neoplasms (SMNs) (5.0%). A substantial burden of non-cancer-related causes of death were also observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A real increase in the incidence of TGCTs and age at diagnosis was confirmed. These trends highlight a shift toward less aggressive treatment while maintaining excellent outcomes. However, the notable occurrence of SMNs and non-cancer mortality underscores the need for long-term follow-up that includes survivorship care beyond oncological monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04068-9","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:00:15Z","timestamp":1760371215000},"page":"1374-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiological patterns, temporal trends in management and long-term outcomes in testicular cancer: a 30-year single center experience"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6803-8228","authenticated-orcid":false,"given":"Patricia","family":"Capdevila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Aparicio Urtasun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"4068_CR1","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1002\/ijc.25517","volume":"127","author":"DM Parkin","year":"2010","unstructured":"Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010;127:2918\u201327.","journal-title":"Int J Cancer"},{"issue":"1","key":"4068_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/andr.293","volume":"3","author":"B Trabert","year":"2015","unstructured":"Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973\u20132007. Andrology. 2015;3(1):4\u201312. https:\/\/doi.org\/10.1111\/andr.293.","journal-title":"Andrology"},{"key":"4068_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1158\/1055-9965.EPI-10-0031","volume":"19","author":"VM Chia","year":"2010","unstructured":"Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973\u20132002. Cancer Epidemiol Biomarkers Prev. 2010;19:1151\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4068_CR4","first-page":"323","volume":"19\u201320","author":"D Forman","year":"1994","unstructured":"Forman D, Moller H. Testicular cancer. Cancer Surv. 1994;19\u201320:323\u201341.","journal-title":"Cancer Surv"},{"issue":"12","key":"4068_CR5","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1055-9965.2157.13.12","volume":"13","author":"L Richiardi","year":"2004","unstructured":"Richiardi L, Bellocco R, Adami HO, Torr\u00e5ng A, Barlow L, Hakulinen T, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2157\u201366.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4068_CR6","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1002\/ijc.21747","volume":"118","author":"F Bray","year":"2006","unstructured":"Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, M\u00f8ller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118:3099\u2013111. https:\/\/doi.org\/10.1002\/ijc.21747.","journal-title":"Int J Cancer"},{"issue":"6","key":"4068_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.eururo.2013.11.004","volume":"65","author":"A Znaor","year":"2014","unstructured":"Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095\u2013106. https:\/\/doi.org\/10.1016\/j.eururo.2013.11.004. (Epub 2013 Nov 14 PMID: 24268506).","journal-title":"Eur Urol"},{"issue":"1","key":"4068_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0494-0","volume":"19","author":"R Schaffar","year":"2019","unstructured":"Schaffar R, Pant S, Bouchardy C, Schubert H, Rapiti E. Testicular cancer in Geneva, Switzerland, 1970\u20132012: incidence trends, survival and risk of second cancer. BMC Urol. 2019;19(1):64. https:\/\/doi.org\/10.1186\/s12894-019-0494-0.","journal-title":"BMC Urol"},{"issue":"1","key":"4068_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2605.2005.00605.x","volume":"29","author":"R Jacobsen","year":"2006","unstructured":"Jacobsen R, M\u00f8ller H, Thoresen S\u00d8, Pukkala E, Kjaer SK, Johansen C. Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int J Androl. 2006;29(1):199\u2013204.","journal-title":"Int J Androl"},{"issue":"4","key":"4068_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/andr.12666","volume":"7","author":"MP Brandt","year":"2019","unstructured":"Brandt MP, Gust KM, Bon D, Tsaur I, Thomas C, Neisius A, et al. Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014. Andrology. 2019;7(4):408\u201314. https:\/\/doi.org\/10.1111\/andr.12666.","journal-title":"Andrology"},{"issue":"5","key":"4068_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","volume":"76","author":"JK Gurney","year":"2019","unstructured":"Gurney JK, Florio AA, Znaor A, Ferlay J, Laversanne M, Sarfati D, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019;76(5):615\u201323. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.002.","journal-title":"Eur Urol"},{"issue":"3","key":"4068_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bju.14148","volume":"122","author":"O Yl\u00f6nen","year":"2018","unstructured":"Yl\u00f6nen O, Jyrkki\u00f6 S, Pukkala E, Syv\u00e4nen K, Bostr\u00f6m PJ. Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries. BJU Int. 2018;122(3):384\u201393. https:\/\/doi.org\/10.1111\/bju.14148.","journal-title":"BJU Int"},{"issue":"3","key":"4068_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.32810","volume":"147","author":"A Znaor","year":"2020","unstructured":"Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Laversanne M, Kuli\u0161 T, Gurney J, et al. Testicular cancer incidence predictions in Europe 2010\u20132035: a rising burden despite population ageing. Int J Cancer. 2020;147(3):820\u20138. https:\/\/doi.org\/10.1002\/ijc.32810.","journal-title":"Int J Cancer"},{"issue":"3","key":"4068_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1620\/tjem.252.219","volume":"252","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Koyama J, Goto T, Fujii S, Yamada S, Kawasaki Y, et al. Trends in age and histology of testicular cancer from 1980\u20132019: a single-center study. Tohoku J Exp Med. 2020;252(3):219\u201324. https:\/\/doi.org\/10.1620\/tjem.252.219.","journal-title":"Tohoku J Exp Med"},{"issue":"2","key":"4068_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/tau-22-521","volume":"12","author":"T Yoneyama","year":"2023","unstructured":"Yoneyama T, Hashimoto Y, Ohyama C. Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study. Transl Androl Urol. 2023;12(2):161\u20137. https:\/\/doi.org\/10.21037\/tau-22-521.","journal-title":"Transl Androl Urol"},{"issue":"1","key":"4068_CR16","doi-asserted-by":"publisher","first-page":"33.e1","DOI":"10.1016\/j.urolonc.2012.12.002","volume":"32","author":"CG Ruf","year":"2014","unstructured":"Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol. 2014;32(1):33.e1-6. https:\/\/doi.org\/10.1016\/j.urolonc.2012.12.002.","journal-title":"Urol Oncol"},{"issue":"4","key":"4068_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdq466","volume":"22","author":"C Kollmannsberger","year":"2011","unstructured":"Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011;22(4):808\u201314. https:\/\/doi.org\/10.1093\/annonc\/mdq466.","journal-title":"Ann Oncol"},{"key":"4068_CR18","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1002\/cncr.31390","volume":"124","author":"MJ Leveridge","year":"2018","unstructured":"Leveridge MJ, Siemens DR, Brennan K, Izard JP, Karim S, An H, et al. Temporal trends in management and outcomes of testicular cancer: a population-based study. Cancer. 2018;124:2724\u201332. https:\/\/doi.org\/10.1002\/cncr.31390.","journal-title":"Cancer"},{"issue":"2","key":"4068_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00345-016-1870-y","volume":"35","author":"SA Yap","year":"2017","unstructured":"Yap SA, Yuh LM, Evans CP, Dall\u2019Era MA, Wagenaar RM, Cress R, et al. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017;35(2):277\u201383.","journal-title":"World J Urol"},{"issue":"10","key":"4068_CR20","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1245\/s10434-011-1722-3","volume":"18","author":"M Sun","year":"2011","unstructured":"Sun M, Abdollah F, Buda\u00fcs L, Liberman D, Tian Z, Morgan M, et al. Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. Ann Surg Oncol. 2011;18(10):2997\u20133004.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4068_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.eururo.2014.07.001","volume":"66","author":"MS Mortensen","year":"2014","unstructured":"Mortensen MS, Lauritsen J, Gundgaard MG, Agerb\u00e6k M, Holm NV, Christensen IJ, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172\u20138.","journal-title":"Eur Urol"},{"issue":"4","key":"4068_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdq466","volume":"22","author":"C Kollmannsberger","year":"2011","unstructured":"Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011;22(4):808\u201314.","journal-title":"Ann Oncol"},{"issue":"34","key":"4068_CR23","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","volume":"32","author":"G Daugaard","year":"2014","unstructured":"Daugaard G, Gundgaard MG, Mortensen MS, Agerb\u00e6k M, Holm NV, R\u00f8rth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32(34):3817\u201323.","journal-title":"J Clin Oncol"},{"key":"4068_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cncr.30332","volume":"123","author":"AB Weiner","year":"2017","unstructured":"Weiner AB, Pearce SM, Eggener SE. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: an analysis of the National Cancer Database. Cancer. 2017;123:245\u201352.","journal-title":"Cancer"},{"issue":"35","key":"4068_CR25","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1200\/JCO.2011.36.0503","volume":"29","author":"J Aparicio","year":"2011","unstructured":"Aparicio J, Maroto P, Del Muro XG, Gum\u00e0 J, S\u00e1nchez-Mu\u00f1oz A, Margel\u00ed M, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35):4677\u201381. https:\/\/doi.org\/10.1200\/JCO.2011.36.0503.","journal-title":"J Clin Oncol"},{"key":"4068_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1464-410X.2011.10887.x","volume":"110","author":"CY Vossen","year":"2012","unstructured":"Vossen CY, Horwich A, Daugaard G, Van PH, Osanto S. Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int. 2012;110:524\u201331.","journal-title":"BJU Int"},{"issue":"3","key":"4068_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bju.14771","volume":"124","author":"F Pishgar","year":"2019","unstructured":"Pishgar F, Haj-Mirzaian A, Ebrahimi H, Saeedi Moghaddam S, Mohajer B, Nowroozi MR, et al. Global, regional and national burden of testicular cancer, 1990\u20132016: results from the global burden of disease study 2016. BJU Int. 2019;124(3):386\u201394.","journal-title":"BJU Int"},{"issue":"1","key":"4068_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13045-021-01213-z","volume":"14","author":"L Lin","year":"2021","unstructured":"Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990\u20132019. J Hematol Oncol. 2021;14(1):197.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4068_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35706","volume":"131","author":"AA Almeida","year":"2025","unstructured":"Almeida AA, Wojt A, Metayer C, Kanetsky PA, Graubard BI, Alvarez CS, et al. Racial\/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992\u20132021. Cancer. 2025;131(2):e35706.","journal-title":"Cancer"},{"issue":"12","key":"4068_CR30","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s00345-022-04145-6","volume":"40","author":"CG Ruf","year":"2022","unstructured":"Ruf CG, Schmidt S, Kliesch S, Oing C, Pfister D, Busch J, et al. Testicular germ cell tumours\u2019 clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol. 2022;40(12):2889\u2013900.","journal-title":"World J Urol"},{"issue":"2","key":"4068_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.eururo.2017.06.013","volume":"73","author":"SC Kamran","year":"2018","unstructured":"Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, et al. Contemporary treatment patterns and outcomes for clinical stage IS testicular cancer. Eur Urol. 2018;73(2):262\u201370.","journal-title":"Eur Urol"},{"key":"4068_CR32","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","volume":"27","author":"T Tandstad","year":"2009","unstructured":"Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009; 27(13): 2122\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4068_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12094-020-02393-9","volume":"23","author":"J Aparicio","year":"2021","unstructured":"Aparicio J, Garc\u00eda Del Muro X, Maroto P, Terrasa J, Castellano D, Bast\u00fas R, et al. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clin Transl Oncol. 2021;23(1):58\u201364.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"4068_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.euo.2023.10.014","volume":"7","author":"JL Boormans","year":"2024","unstructured":"Boormans JL, Sylvester R, Anson-Cartwright L, Glicksman RM, Hamilton RJ, Hahn E, et al. Prognostic factor risk groups for clinical stage I seminoma: an individual patient data analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol. 2024;7(3):537\u201343.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"4068_CR35","doi-asserted-by":"publisher","first-page":"135.e17","DOI":"10.1016\/j.urolonc.2020.11.004","volume":"39","author":"P Maroto","year":"2021","unstructured":"Maroto P, Garc\u00eda Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, et al. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. Urol Oncol. 2021;39(2):135.e17-135.e23.","journal-title":"Urol Oncol"},{"issue":"5","key":"4068_CR36","volume":"33","author":"M Khan","year":"2025","unstructured":"Khan M, Sheehan PK, Bazin A, Farooq AR, Leonard C, Aleem U, et al. Long-term side effects of testicular cancer and treatment (observational study of mortality and morbidity in testicular cancer survivors). Support Care Cancer. 2025;33(5):413.","journal-title":"Support Care Cancer"},{"key":"4068_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0959-8049(96)00459-5","volume":"33","author":"EH Wanderas","year":"1997","unstructured":"Wanderas EH, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer. 1997;33:244\u201352.","journal-title":"Eur J Cancer"},{"key":"4068_CR38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/jnci\/83.19.1391","volume":"83","author":"A \u00d8sterlind","year":"1991","unstructured":"\u00d8sterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, et al. Risk of bilateral testicular germ cell cancer in Denmark: 1960\u20131984. J Natl Cancer Inst. 1991;83:1391\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"4068_CR39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/jnci\/dji185","volume":"97","author":"SD Fossa","year":"2005","unstructured":"Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97:1056\u201366.","journal-title":"J Natl Cancer Inst"},{"key":"4068_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.juro.2007.03.027","volume":"178","author":"B Akdogan","year":"2007","unstructured":"Akdogan B, Divrik RT, Tombul T, Yazici S, Tasar C, Zorlu F. Bilateral testicular germ cell tumors in Turkey: increase in incidence in last decade and evaluation of risk factors in 30 patients. J Urol. 2007;178:129\u201333.","journal-title":"J Urol"},{"key":"4068_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00432-003-0437-7","volume":"129","author":"L Geczi","year":"2003","unstructured":"Geczi L, Gomez F, Bak M, Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol. 2003;129:309\u201315.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4068_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/02841860510029923","volume":"44","author":"M Hentrich","year":"2005","unstructured":"Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Management and outcome of bilateral testicular germ cell tumors: twenty-five year experience in Munich. Acta Oncol. 2005;44:529\u201336.","journal-title":"Acta Oncol"},{"key":"4068_CR43","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/ijc.25943","volume":"129","author":"KE Andreassen","year":"2011","unstructured":"Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fossa SD. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953\u20132007). Int J Cancer. 2011;129:2867\u201374.","journal-title":"Int J Cancer"},{"key":"4068_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/1008-682X.122069","volume":"16","author":"C Rusner","year":"2014","unstructured":"Rusner C, Streller B, Stegmaier C, Trocchi P, Kuss O, McGlynn KA, et al. Risk of second primary cancers after testicular cancer in East and West Germany: a focus on contralateral testicular cancers. Am J Androl. 2014;16:285\u20139.","journal-title":"Am J Androl"},{"issue":"4","key":"4068_CR45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.6004\/jnccn.2012.0052","volume":"10","author":"C Fung","year":"2012","unstructured":"Fung C, Fossa SD, Beard CJ, Travis LB. Second malignant neoplasms in testicular cancer survivors. J Natl Compr Canc Netw. 2012;10(4):545\u201356. https:\/\/doi.org\/10.6004\/jnccn.2012.0052.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"4068_CR46","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00345-023-04515-8","volume":"1","author":"H Fu","year":"2023","unstructured":"Fu H, Talluri S, Rai S, Liang L, Trivedi J, Ankem MK. Identification of risk factors and prediction models for secondary malignant neoplasms (SMNs)-free survival and SMNs-specific survival in testicular cancer survivors. World J Urol. 2023;1(9):2413\u201320.","journal-title":"World J Urol"},{"issue":"21","key":"4068_CR47","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1200\/JCO.2011.34.6379","volume":"29","author":"C van Walraven","year":"2011","unstructured":"van Walraven C, Fergusson D, Earle C, Baxter N, Alibhai S, MacDonald B, et al. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol. 2011;29(21):2883\u20138.","journal-title":"J Clin Oncol"},{"key":"4068_CR48","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2008.10.005","volume":"181","author":"TV Tarin","year":"2009","unstructured":"Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancerassociated with imaging related radiation during surveillance forstage I testicular cancer using computerized tomography. J Urol. 2009;181:627\u201332.","journal-title":"J Urol"},{"issue":"28","key":"4068_CR49","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","volume":"33","author":"C Fung","year":"2015","unstructured":"Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2015;33(28):3105\u201315.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4068_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/djk111","volume":"99","author":"SD Foss\u00e5","year":"2007","unstructured":"Foss\u00e5 SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533\u201344.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4068_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12894-023-01309-3","volume":"23","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li B, Xing J, Gong Z, Xu A, Wang Z. Causes of death after testicular cancer diagnosis: a US population-based analysis. BMC Urol. 2023;23(1):144.","journal-title":"BMC Urol"},{"issue":"6","key":"4068_CR52","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/cncr.31876","volume":"125","author":"AM Saad","year":"2019","unstructured":"Saad AM, Gad MM, Al-Husseini MJ, AlKhayat MA, Rachid A, Alfaar AS, et al. Suicidal death within a year of a cancer diagnosis: a population-based study. Cancer. 2019;125(6):972\u20139.","journal-title":"Cancer"},{"issue":"6","key":"4068_CR53","first-page":"817","volume":"21","author":"S Alanee","year":"2012","unstructured":"Alanee S, Russo P. Suicide in men with testis cancer. Eur J Cancer Care (Engl). 2012;21(6):817\u201321.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"10","key":"4068_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.clon.2010.06.004","volume":"22","author":"EM Teoh","year":"2010","unstructured":"Teoh EM, Dearnaley DP, Horwich A, Van As N, Riley U, Huddart RA. The efficacy of preventing neutropenic sepsis in patients with testicular germ cell tumours: results of two consecutive audits. Clin Oncol (R Coll Radiol). 2010;22(10):891\u20132.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"4068_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5489\/cuaj.8009","volume":"16","author":"NS Shrem","year":"2022","unstructured":"Shrem NS, Wood L, Hamilton RJ, Kuhathaas K, Czaykowski P, Roberts M, et al. Testicular cancer survivorship: long-term toxicity and management. Can Urol Assoc J. 2022;16(8):257\u201372. https:\/\/doi.org\/10.5489\/cuaj.8009.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"4068_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12094-024-03546-w","volume":"27","author":"B Herrero","year":"2025","unstructured":"Herrero B, Carde\u00f1a-Guti\u00e9rrez A, Godoy A, Gonzaga A, Grueso AM, Nu\u00f1o A, et al. Exercise in cancer patients: assistance levels and referral pathways-a position statement from the Spanish Society of Medical Oncology. Clin Transl Oncol. 2025;27(1):108\u201316.","journal-title":"Clin Transl Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04068-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:29Z","timestamp":1774415609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04068-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4068"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04068-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the institutional review board of Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived due to the retrospective nature of the study and anonymization of patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}